Antagonism of stromal cell-derived factor-1alpha reduces infarct size and improves ventricular function after myocardial infarction.

To examine the biological impact of locally expressed stromal cell-derived factor-1alpha (SDF-1alpha) during the acute phase of remodeling after myocardial infarction (MI), rats were treated with the selective CXCR4 receptor antagonist AMD3100 (1 mg/kg; given 24 h post-MI and continued for 6 days). In 1-week post-MI rats, intense SDF-1 immunoreactivity was detected in scar-residing vessels, and SDF-1alpha messenger ribonucleic acid (mRNA) levels were significantly greater in the infarct region compared to the noninfarcted left ventricle (NILV). AMD3100 treatment of post-MI rats reduced infarct size, improved systolic function, and partially suppressed the increased expression of atrial natriuretic peptide mRNA in the NILV. The latter finding indirectly suggests that SDF-1alpha may have contributed to the hypertrophic response of the NILV. SDF-1alpha treatment of neonatal rat ventricular myocytes (NNVMs) failed to promote protein synthesis. However, in hypertrophied NNVMs, SDF-1alpha treatment further augmented (3)H-leucine uptake, and AMD3100 selectively inhibited the increase in protein synthesis. Collectively, these data support the existence of an SDF-1alpha gradient in the damaged rat myocardium increasing toward the infarct region and highlight the novel observation that AMD3100 antagonism of the SDF-1alpha/CXCR4 axis reduced scar expansion and improved contractility. In vitro data further suggest that SDF-1alpha may have contributed to the hypertrophic response of the NILV.
AuthorsCindy Proulx, Viviane El-Helou, Hugues Gosselin, Robert Clement, Marc-Antoine Gillis, Louis Villeneuve, Angelino Calderone
JournalPflu╠łgers Archiv : European journal of physiology (Pflugers Arch) Vol. 455 Issue 2 Pg. 241-50 (Nov 2007) ISSN: 0031-6768 [Print] Germany
PMID17520275 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Chemokine CXCL12
  • Cxcr4 protein, rat
  • Heterocyclic Compounds
  • RNA, Messenger
  • Receptors, CXCR4
  • JM 3100
  • Animals
  • Chemokine CXCL12 (antagonists & inhibitors, metabolism)
  • Disease Models, Animal
  • Heterocyclic Compounds (pharmacology, therapeutic use)
  • Hypertrophy, Left Ventricular (drug therapy, physiopathology)
  • Male
  • Myocardial Infarction (drug therapy, metabolism, pathology)
  • RNA, Messenger (metabolism)
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, CXCR4 (antagonists & inhibitors, physiology)
  • Ventricular Dysfunction, Left (drug therapy, physiopathology)
  • Ventricular Remodeling (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: